Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019.
Sean Wei Xiang OngWilnard Yeong Tze TanYi-Hao ChanSiew-Wai FongShanshan W HowlandLisa F P NgYee Sin LeoDavid Chien Boon LyeBarnaby Edward YoungPublished in: Clinical & translational immunology (2020)
Treatment with COX-2 inhibitors was not associated with an increase in adverse outcomes. Its potential for therapeutic use as an immune modulator warrants further evaluation in a large randomised controlled trial.